TY - JOUR
T1 - Primary lateral sclerosis (PLS) functional rating scale
T2 - PLS-specific clinimetric scale
AU - the PLSFRS study group
AU - Mitsumoto, Hiroshi
AU - Chiuzan, Codruta
AU - Gilmore, Madison
AU - Zhang, Yuan
AU - Simmons, Zachary
AU - Paganoni, Sabrina
AU - Kisanuki, Yasushi Y.
AU - Zinman, Lorne
AU - Jawdat, Omar
AU - Sorenson, Eric
AU - Floeter, Mary Kay
AU - Pioro, Erik P.
AU - Fernandes Filho, J. Americo M.
AU - Heitzman, Daragh
AU - Fournier, Christina Nicole
AU - Oskarsson, Bjorn
AU - Heiman-Patterson, Terry
AU - Maragakis, Nicholas
AU - Joyce, Nanette
AU - Hayat, Ghazala
AU - Nations, Sharon
AU - Scelsa, Stephen
AU - Walk, David
AU - Elman, Lauren
AU - Hupf, Jonathan
AU - McHale, Brittany
N1 - Publisher Copyright:
© 2019 Wiley Periodicals, Inc.
PY - 2020/2/1
Y1 - 2020/2/1
N2 - Introduction: Our research aim was to develop a novel clinimetric scale sensitive enough to detect disease progression in primary lateral sclerosis (PLS). Methods: A prototype of the PLS Functional Rating Scale (PLSFRS) was generated. Seventy-seven participants with PLS were enrolled and evaluated at 21 sites that comprised the PLSFRS study group. Participants were assessed using the PLSFRS, Neuro-Quality of Life (QoL), Schwab-England Activities of Daily Living (ADL), and the Clinical Global Impression of Change scales. Participants completed telephone assessments at 12, 24, and 48 weeks after enrollment. Results: The PLSFRS demonstrated internal consistency as well as intrarater, interrater, telephone test-retest reliability, and construct validity. Significant changes in disease progression were detected at 6 and 12 months; changes measured by the PLSFRS vs the ALSFRS-R were significantly higher. Discussion: The PLSFRS is a valid tool to assess the natural history of PLS in a shorter study period.
AB - Introduction: Our research aim was to develop a novel clinimetric scale sensitive enough to detect disease progression in primary lateral sclerosis (PLS). Methods: A prototype of the PLS Functional Rating Scale (PLSFRS) was generated. Seventy-seven participants with PLS were enrolled and evaluated at 21 sites that comprised the PLSFRS study group. Participants were assessed using the PLSFRS, Neuro-Quality of Life (QoL), Schwab-England Activities of Daily Living (ADL), and the Clinical Global Impression of Change scales. Participants completed telephone assessments at 12, 24, and 48 weeks after enrollment. Results: The PLSFRS demonstrated internal consistency as well as intrarater, interrater, telephone test-retest reliability, and construct validity. Significant changes in disease progression were detected at 6 and 12 months; changes measured by the PLSFRS vs the ALSFRS-R were significantly higher. Discussion: The PLSFRS is a valid tool to assess the natural history of PLS in a shorter study period.
UR - http://www.scopus.com/inward/record.url?scp=85077028533&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85077028533&partnerID=8YFLogxK
U2 - 10.1002/mus.26765
DO - 10.1002/mus.26765
M3 - Article
C2 - 31758557
AN - SCOPUS:85077028533
SN - 0148-639X
VL - 61
SP - 163
EP - 172
JO - Muscle and Nerve
JF - Muscle and Nerve
IS - 2
ER -